Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 5, 2013, Pages 593-600

  Reilly, M ^a   Miller, R M ^b   Thomson, M H ^b   Patris, V ^b   Ryle, P ^c   Mcloughlin, L ^c   Mutch, P ^b   Gilboy, P ^a   Miller, C ^d   Broekema, M ^e   Keogh, B ^a   Mccormack, W ^a   Van De Wetering De Rooij, J ^e  

^a Opsona Therapeutics Ltd   (Ireland)

^b ICON PLC   (United Kingdom)

^c PR BioServices   (United Kingdom)

^d Quotient Bioresearch Ltd   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ANTIBODY; INTERLEUKIN 6; OPN 305; PLACEBO; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; BONE PAIN; CAROTID ARTERY INJURY; CEREBROVASCULAR ACCIDENT; CONJUNCTIVITIS; CONTROLLED STUDY; CONTUSION; DEFECATION HABIT; DEPIGMENTATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; EXTERNAL OTITIS; FLATULENCE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LEUKOCYTE COUNT; LIGAMENT RUPTURE; MALE; MONOCYTE; MYALGIA; NORMAL HUMAN; OROPHARYNX PAIN; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; POSITIONAL DIZZINESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; LEUKOCYTE COUNT; MALE; MIDDLE AGED; TOLL-LIKE RECEPTOR 2; YOUNG ADULT;

EID: 84886725015     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.150     Document Type: Article

References (13)

1. Farrar, C.A. et al. Inhibition of TLR2 promotes graft function in a murine model of renal transplant ischemia-reperfusion injury. FASEB J. 26, 799-807 (2012).
2. Jochmans, I. et al. Machine perfusion versus cold storage for the preservation of kidneys donated after cardiac death: A multicenter, randomized, controlled trial. Ann. Surg. 252, 756-764 (2010).
3. Andrés, A. et al.; NI2A Study Group. A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function. Clin. Transplant. 23, 23-32 (2009).
4. Arslan, F., Keogh, B., McGuirk, P. & Parker, A.E. TLR2 and TLR4 in ischemia reperfusion injury. Mediators Inflamm. 2010, 704202 (2010).
5. Wolfs, T.G. et al. In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. J. Immunol. 168, 1286-1293 (2002).
6. Meldrum, K.K., Meldrum, D.R., Meng, X., Ao, L. & Harken, A.H. TNF-alphadependent bilateral renal injury is induced by unilateral renal ischemiareperfusion. Am. J. Physiol. Heart Circ. Physiol. 282, H540-H546 (2002).
7. Anders, H.J., Banas, B. & Schlöndorff, D. Signaling danger: Toll-like receptors and their potential roles in kidney disease. J. Am. Soc. Nephrol. 15, 854-867 (2004).
8. Asea, A. et al. Novel signal transduction pathway utilized by extracellular HSP70: Role of toll-like receptor (TLR) 2 and TLR4. J. Biol. Chem. 277, 15028-15034 (2002).
9. Li, M. et al. An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J. Immunol. 166, 7128-7135 (2001).
10. Padanilam, B.J. Cell death induced by acute renal injury: A perspective on the contributions of apoptosis and necrosis. Am. J. Physiol. Renal Physiol. 284, F608-F627 (2003).
11. Arslan, F. et al. Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ. Cardiovasc. Interv. 5, 279-287 (2012).
12. Lim, S.W. et al. Cyclosporine-induced renal injury induces toll-like receptor and maturation of dendritic cells. Transplantation 80, 691-699 (2005).
13. Daugherty, A.L. & Mrsny, R.J. Formulation and delivery issues for monoclonal antibody therapeutics. Adv. Drug Deliv. Rev. 58, 686-706 (2006).